Incidence of Febrile Neutropenia in Advanced Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy in Korea and Its Impact on Prognosis
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The concurrent regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) has been categorized as a high-risk factor for febrile neutropenia (FN). The incidence of FN was reported to be as high as 17%–26% in studies conducted in Western countries. However, these rates may vary among different ethnic groups. This study aimed to evaluate the incidence of FN and its effect on prognosis following adjuvant TAC chemotherapy in Korean patients with advanced breast cancer. Methods: We analyzed data from 187 patients who received 6 cycles of adjuvant TAC chemotherapy between July 2005 and December 2014. No patients received long-acting granulocyte-colony stimulating factor (G-CSF) as primary prophylaxis for FN due to guidelines for cost reimbursement in Korea. The incidence rates of FN, dose reduction of TAC, relative dose intensity (RDI), relapse-free survival (RFS), and overall survival (OS) were investigated. Results: A total of 102 (54.5%) patients experienced FN, especially older patients (51 years vs. 49 years, p=0.045). RDI was lower in patients with FN than in those without (96.4% vs. 99.5%, p=0.001, respectively). Death was reported in 2 patients (2.35%) without FN and in 10 patients (9.80%) with FN (hazard ratio [HR]: 6.64; 95% confidence interval [CI]: 1.28 to 34.36; p=0.024). No significant differences in RFS (p=0.235) were found using Kaplan-Meier analysis. Conclusion: The incidence of FN was significantly higher in Korea than in Western countries, and FN had a negative impact on the patients’ prognosis. Primary prophylactic G-CSF should be prioritized in Korean patients with advanced breast cancer who receive adjuvant TAC chemotherapy.
Abstract
Purpose: The concurrent regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) has been categorized as a high-risk factor for febrile neutropenia (FN). The incidence of FN was reported to be as high as 17%–26% in studies conducted in Western countries. However, these rates may vary among different ethnic groups. This study aimed to evaluate the incidence of FN and its effect on prognosis following adjuvant TAC chemotherapy in Korean patients with advanced breast cancer. Methods: We analyzed data from 187 patients who received 6 cycles of adjuvant TAC chemotherapy between July 2005 and December 2014. No patients received long-acting granulocyte-colony stimulating factor (G-CSF) as primary prophylaxis for FN due to guidelines for cost reimbursement in Korea. The incidence rates of FN, dose reduction of TAC, relative dose intensity (RDI), relapse-free survival (RFS), and overall survival (OS) were investigated. Results: A total of 102 (54.5%) patients experienced FN, especially older patients (51 years vs. 49 years, p=0.045). RDI was lower in patients with FN than in those without (96.4% vs. 99.5%, p=0.001, respectively). Death was reported in 2 patients (2.35%) without FN and in 10 patients (9.80%) with FN (hazard ratio [HR]: 6.64; 95% confidence interval [CI]: 1.28 to 34.36; p=0.024). No significant differences in RFS (p=0.235) were found using Kaplan-Meier analysis. Conclusion: The incidence of FN was significantly higher in Korea than in Western countries, and FN had a negative impact on the patients’ prognosis. Primary prophylactic G-CSF should be prioritized in Korean patients with advanced breast cancer who receive adjuvant TAC chemotherapy.
참고문헌 (24)
- Gradishar WJ, "Breast cancer version 2.2015", J Natl Compr Canc Netw, 13, pp.448~475 (2015)
- Senkus E, "Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 24, pp.vi7~vi23 (2013)
- Mackey JR, "Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial", Lancet Oncol, 14, pp.72~80 (2013)
- Martin M, "Adjuvant docetaxel for node-positive breast cancer", N Engl J Med, 352, pp.2302~2313 (2005)
- Roche H, "Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial", J Clin Oncol, 24, pp.5664~5671 (2006)
- Martin M, "Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer", J Natl Cancer Inst, 100, pp.805~814 (2008)
- Aapro MS, "2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours", Eur J Cancer, 47, pp.8~32 (2011)
- Smith TJ, "2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline", J Clin Oncol, 24, pp.3187~3205 (2006)
- Dale DC, "Colony-stimulating factors for the management of neutropenia in cancer patients", Drugs, 62, pp.1~15 (2002)
- Kuderer NM, "Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review", J Clin Oncol, 25, pp.3158~3167 (2007)
- Bennett CL, "Colony-stimulating factors for febrile neutropenia during cancer therapy", N Engl J Med, 368, pp.1131~1139 (2013)
- Lupichuk S, "Real-world adjuvant TAC or FEC-D for HER2-negative node-positive breast cancer in women less than 50 years of age", Curr Oncol, 23, pp.164~170 (2016)
- Barcenas CH, "Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer", J Clin Oncol, 32, pp.2010~2017 (2014)
- Lee J, "Toxicity and quality of life of Korean breast cancer patients treated with docetaxel-containing chemotherapy without primary G-CSF prophylaxis", Breast Cancer, 21, pp.670~676 (2014)
- Weycker D, "Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice", Breast Cancer Res Treat, 133, pp.301~310 (2012)
- Boer K, "Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC)", Pathol Oncol Res, 9, pp.166~169 (2003)
- Mackey JR, "Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial", Ann Oncol, 27, pp.1041~1047 (2016)
- 우희두, "한국 유방암 환자에서 TAC 보조항암화학요법의 독성 및 내성에 대한 연구", Journal of Breast Cancer, 14, pp.44~49 (2011), 한국유방암학회
- Hor SY, "PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients", Pharmacogenomics J, 8, pp.139~146 (2008)
- Lalami Y, "Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data", Crit Rev Oncol Hematol, 120, pp.163~179 (2017)
- Culakova E, "The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study", Springerplus, 4, pp.396~405 (2015)
- Chirivella I, "Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients", Breast Cancer Res Treat, 114, pp.479~484 (2009)
- Colleoni M, "Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International breast cancer study group", Eur J Cancer, 34, pp.1693~1700 (1998)
- Chia VM, "Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy", Breast Cancer Res Treat, 138, pp.621~631 (2013)